Prohost Letter #406
A Special Prohost Issue
REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES
Vertex (VRTX): Great news about 2016 revenues & earnings Growth and pipeline.
FROM YESTERDAY: Tremendous Revenues Growth. Cystic fibrosis (CF) revenues grew up around 75%.
FOR TOMORROW: Boosting the pipeline value by Advancing CF novel correctors into
Phase 2 trials while Producing and advancing new CF correctors.
PROJECTIONS: Continued revenues and earnings growth in 2017. Progress in . . .